- AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
May 10, 2026 · youtube.com
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.
- Natera Q1 Earnings Call Highlights
May 8, 2026 · marketbeat.com
Natera NASDAQ: NTRA reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief Executive Officer Steve Chapman said strong performance in women's health and another record quarter in oncology drove the results, while Chief Financial Officer Michael Brophy highlighted continued improvement in realized pricing and reimbursement dynamics.
- Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates
May 7, 2026 · zacks.com
Natera (NTRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
- Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
May 7, 2026 · seekingalpha.com
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
- Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7, 2026 · zacks.com
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Natera Reports First Quarter 2026 Financial Results
May 7, 2026 · businesswire.com
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an increase of 38.8%. Generated a gross margin1 of 64.7% in the first quarter of 2026, compared to a gross margin1 of 63.1% in the first quarter.
- NATERA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
May 7, 2026
AUSTIN, TEXAS--(BUSINESS WIRE)--NATERA, INC. (NASDAQ: NTRA), A GLOBAL LEADER IN CELL-FREE DNA AND GENETIC TESTING, TODAY REPORTED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. RECENT FINANCIAL HIGHLIGHTS GENERATED TOTAL REVENUES OF $696.6 MILLION IN THE FIRST QUARTER OF 2026, COMPARED TO $501.8 MILLION IN THE FIRST QUARTER OF 2025, AN INCREASE OF 38.8%. GENERATED A GROSS MARGIN1 OF 64.7% IN THE FIRST QUARTER OF 2026, COMPARED TO A GROSS MARGIN1 OF 63.1% IN THE FIRST QUARTER.
- Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLT
Apr 22, 2026 · businesswire.com
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a broad body of evidence supporting its Prospera test at the 2026 International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting. Prospera will be featured in 17 abstracts, including six oral presentations. Together with academic colleagues, Natera will highlight Prospera's expanding clinical utility in heart and lung transplantation, spanning re.
- PROSPERA™ EVIDENCE IN HEART AND LUNG TRANSPLANTATION FEATURED ACROSS 17 PRESENTATIONS AT ISHLT
Apr 22, 2026
AUSTIN, TEXAS--(BUSINESS WIRE)--NATERA, INC. (NASDAQ: NTRA), A GLOBAL LEADER IN CELL-FREE DNA AND PRECISION MEDICINE, TODAY ANNOUNCED A BROAD BODY OF EVIDENCE SUPPORTING ITS PROSPERA TEST AT THE 2026 INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION (ISHLT) ANNUAL MEETING. PROSPERA WILL BE FEATURED IN 17 ABSTRACTS, INCLUDING SIX ORAL PRESENTATIONS. TOGETHER WITH ACADEMIC COLLEAGUES, NATERA WILL HIGHLIGHT PROSPERA'S EXPANDING CLINICAL UTILITY IN HEART AND LUNG TRANSPLANTATION, SPANNING RE.
- Merit Financial Group LLC Buys 4,610 Shares of Natera, Inc. $NTRA
Apr 20, 2026 · defenseworld.net
Merit Financial Group LLC lifted its stake in Natera, Inc. (NASDAQ: NTRA) by 32.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,720 shares of the medical research company's stock after acquiring an additional 4,610 shares during the period.